Clay Siegall Uploads an Interesting Article on Hurdles in Decision Making on His Official Blog

Clay Siegall recently posted on his official blog about making choices as explained by several philosophers. Ruth Chang, a professor of philosophy at Rutgers University, noted that understanding hard choices unveil personal strength that is within every individual. Hard choices can be as easy as choosing what to have for breakfast. She advises that if faced with a hard choice, one shouldn’t think that he or she is stupid. She also noted that fear of the outcome often leads people to take the safest choices. She advises people not to only see choices as better, worse, or equal. Instead, they should take them at par, consider what matters, commit to one, and create reasons as to why they have opted for one choice and not the other.

Sheena Iyengar noted that what makes people unable to make decisions easily is when they have many options. They start thinking of the methods for analyzing the options. Another hurdle is when one is well aware of the consequences. She noted that culture also influences decision making. A culture that values togetherness will influence people to make a choice based on the social responsibility while one that values independence will influence people to make a decision based on what they like.

About Clay Siegall.

Clay B. Siegall is the co-founder, CEO, President, and the Board Chairman of Seattle Genetics, a company founded on drug making practices, diligent medical research, and scientific innovations. In his leadership, the company has developed antibody drug conjugates (ADC), the first innovation being ADCETRIS, which gained FDA approval in 2011. Working together with Takeda Pharmaceuticals, ADCETRIS is now a household name worldwide. Mr. Siegall has led the company in obtaining licenses for its ADC technology with Genentech (Roche), AbbVie, GlaxoSmithKline, and Pfizer. Seattle Genetics has marked more than 20 ADCs in clinical development through internal and external programs. Mr. Siegall has played a big role in raising the company’s capital including floating the initial public offer in 2001.

Involvement in Cancer Treatment Research

Inspired by losing his father to brain cancer, Mr. Siegall and Seattle Genetics have been actively involved in researching for better cancer treatments. He has worked with leading research institutes, including the National Institute of Health, The National Cancer Institute, and Bristol-Myers.